Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
Trial details
- Registry ID
- NCT05543928
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary HyperparathyroidismNCT05543928 | OPK | Phase 3 | Terminated | 2024-06-19Actual |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric ParticipantsNCT07494045 | OPK | Phase 2 | Recruiting | 2027-10Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |